<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02923180</url>
  </required_header>
  <id_info>
    <org_study_id>J1693</org_study_id>
    <secondary_id>IRB00103776</secondary_id>
    <nct_id>NCT02923180</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer</brief_title>
  <official_title>A Phase II Trial of Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate- and High-Risk Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MacroGenics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the safety, anti-tumor effect, and immunogenicity of Enoblituzumab given&#xD;
      before radical prostatectomy. All patients will receive Enoblituzumab for 6 weekly doses&#xD;
      beginning 50 days prior to radical prostatectomy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, single arm, open-label phase II study evaluating the safety,&#xD;
      anti-tumor effect, and immunogenicity of neoadjuvant MGA271 given prior to radical&#xD;
      prostatectomy in men with intermediate and high-risk localized prostate cancer. Eligible&#xD;
      patients will receive MGA271 at a dose of 15mg/kg IV given weekly for 6 doses beginning 50&#xD;
      days prior to radical prostatectomy. 14 days after the last dose of MGA271, prostate glands&#xD;
      will be harvested at the time of radical prostatectomy, and prostate tissue will be examined&#xD;
      for the secondary endpoints. Follow-up evaluation for adverse events will occur 30 days and&#xD;
      90 days after surgery. Patients will then be followed by their urologists according to&#xD;
      standard institutional practices, but will require PSA evaluations every 3 (±1) months during&#xD;
      year 1 and every 6 (±2) months during years 2-3.&#xD;
&#xD;
      In Amendment 1, the study was expanded to enroll an additional 16 patients for a total of 32&#xD;
      patients to continue evaluating safety and better estimate the clinical benefit of&#xD;
      Enoblituzumab in terms of undetectable PSA level (&lt;0.1 ng/mL) at 12 months following radical&#xD;
      prostatectomy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 14, 2017</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Actual">August 11, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment-related Adverse Events</measure>
    <time_frame>2 years</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by the Common Terminology Criteria for Adverse Events (CTCAE)v4.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of Neoadjuvant Enoblituzumab as Assessed by PSA0 Response Rate</measure>
    <time_frame>12 months</time_frame>
    <description>Number of participants with undetectable Prostate Specific Antigen (PSA &lt;0.1 ng/mL) at 12 months following radical prostatectomy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quantify Markers of Apoptosis in Prostate Tumor Specimens of Treated Patients</measure>
    <time_frame>up to 3 years post-prostatectomy</time_frame>
    <description>Quantify markers of apoptosis in prostate tumor specimens of treated patients using TUNEL staining and expressed as the mean staining percentage in tumor tissue</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of Cell Proliferation</measure>
    <time_frame>up to 3 years post-prostatectomy</time_frame>
    <description>Quantify markers of cell proliferation in prostate tumor specimens of treated patients using Ki-67 staining and expressed by the mean staining percentage in tumor tissue</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD8+ T Cell Infiltration</measure>
    <time_frame>up to 3 years post-prostatectomy</time_frame>
    <description>Number of CD8+ T-cells in harvested prostate glands from treated patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD-L1 Expression</measure>
    <time_frame>up to 3 years post-prostatectomy</time_frame>
    <description>Mean staining percentage of PD-L1 in tumor tissue, assessed by immunohistochemistry (IHC) in the primary core specimens (pre-treatment) and the prostatectomy surgical specimens (post-treatment).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regulatory T Cell (Treg) Infiltration</measure>
    <time_frame>up to 3 years post-prostatectomy</time_frame>
    <description>Mean staining percentage of Treg cells in tumor tissue of treated patients, assessed through immunohistochemistry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4+ T Cell Infiltration</measure>
    <time_frame>up to 3 years post-prostatectomy</time_frame>
    <description>Mean staining percentage of CD4+ T-cells in tumor tissue of treated patients, assessed through immunohistochemistry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Natural Killer (NK) Cell Density</measure>
    <time_frame>up to 3 years post-prostatectomy</time_frame>
    <description>Mean staining percentage of NK cells in harvested prostate glands.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Enoblituzumab (MGA271) Drug Distribution Evaluated by Detection of MGA271 in Tumor Tissue</measure>
    <time_frame>3 years</time_frame>
    <description>Number of participants with positive or negative MGA271 detection in post-treatment prostate tumor specimens, as evaluated by IHC of fresh frozen sections.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological Complete Responses (pCR)</measure>
    <time_frame>3 years</time_frame>
    <description>Number of participants who achieve pCR, defined as absence of tumor identification on standard histological analysis of resected prostate specimens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA Response Rates</measure>
    <time_frame>3 months post-prostatectomy</time_frame>
    <description>Number of participants with undetectable PSA (&lt;0.1 ng/mL) at 3 months after prostatectomy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to PSA Recurrence</measure>
    <time_frame>up to 3 years post-prostatectomy</time_frame>
    <description>Median time from prostatectomy to time when PSA is ≥ 0.2 ng/mL. Estimated using Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gleason Grade Group Change</measure>
    <time_frame>Day 50</time_frame>
    <description>Number of participants with change in Gleason grade group from pre-treatment biopsy vs. post-treatment biopsy. &quot;Downgrade&quot; refers to a net grade group change less than zero, &quot;upgrade&quot; refers to net grade group change more than zero, and &quot;no change&quot; refers to stable Gleason grade group. Gleason grade groups are defined as grade group 1 (Gleason score ≤ 6), grade group 2 (Gleason score 3+4=7), grade group 3 (Gleason score 4+3=7), grade group 4 (Gleason score 8), and grade group 5 (Gleason scores 9-10).The lower the grade group, the better the outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With PSA Percentage Decrease Prior to Radical Prostatectomy.</measure>
    <time_frame>50 Days</time_frame>
    <description>The PSA percentage change is calculated as the difference from the PSA at day 50 prior to prostatectomy and PSA at screening. A negative value of PSA percentage change (&quot;PSA percentage &lt; 0&quot;) indicates a decrease in PSA from screening, and a positive value (PSA percentage change &gt;= 0) indicates an increase in PSA from screening.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Androgen Receptor (AR) Quantification</measure>
    <time_frame>up to 3 years post-prostatectomy</time_frame>
    <description>Mean staining percentage of AR in harvested prostate tissue, assessed by immunohistochemistry (IHC) staining for AR protein.</description>
  </other_outcome>
  <other_outcome>
    <measure>Tissue Androgen Concentrations</measure>
    <time_frame>up to 3 years post prostatectomy</time_frame>
    <description>Concentration (picogram/3 mg) of testosterone and 5α-dihydrotestosterone (DHT) in prostate tissue.</description>
  </other_outcome>
  <other_outcome>
    <measure>Global Expression Profiling of Tumor Tissues</measure>
    <time_frame>up to 3 years post-prostatectomy</time_frame>
    <description>Number of participants with changes in cellular composition, upregulation and downregulation of immune checkpoints, and other markers of activity versus exhaustion.</description>
  </other_outcome>
  <other_outcome>
    <measure>IHC Analyses of CD137, CD16 and/or CD107A</measure>
    <time_frame>up to 3 years post-prostatectomy</time_frame>
    <description>CD137, CD107A, and CD16 expression in prostate tumor specimens will be assessed by immunohistochemistry (IHC) in the prostatectomy surgical specimens (post-treatment). This endpoint will be expressed as the mean staining percentage of each of these in tumor tissue</description>
  </other_outcome>
  <other_outcome>
    <measure>TCR Repertoire</measure>
    <time_frame>up to 3 years post-prostatectomy</time_frame>
    <description>Number of participants with changes in T-cell receptor (TCR) repertoire, assessed by TCR sequencing.</description>
  </other_outcome>
  <other_outcome>
    <measure>FC Receptor Genotyping</measure>
    <time_frame>up to 3 years post-prostatectomy</time_frame>
    <description>Number of participants with CD16A, CD32A, and CD32B on Fc receptor.</description>
  </other_outcome>
  <other_outcome>
    <measure>PBLs</measure>
    <time_frame>up to 3 years post-prostatectomy</time_frame>
    <description>Number of participants with upregulation and downregulation of immune checkpoints and other markers of activity versus exhaustion, as assessed by flow cytometry at treatment day 1 (pre-treatment), treatment day 36 (post-treatment), and 30 days post-prostatectomy.</description>
  </other_outcome>
  <other_outcome>
    <measure>B7-H3 Expression</measure>
    <time_frame>up to 3 years post-prostatectomy</time_frame>
    <description>B7-H3 expression in prostate tumor specimens will be assessed by IHC (immunohistochemistry) in the primary core specimens (pre-treatment) and in the prostatectomy surgical specimens (post-treatment). This endpoint will be expressed as the mean staining percentage of B7-H3 in tumor tissue.</description>
  </other_outcome>
  <other_outcome>
    <measure>PD-1, LAG3, and TIM3 Expression</measure>
    <time_frame>up to 3 Years post-prostatectomy</time_frame>
    <description>PD-1, LAG3, and TIM3 expression in prostate tumor specimens will be assessed by IHC (immunohistochemistry) in the primary core specimens (pre-treatment) and in the prostatectomy surgical specimens (post-treatment). This endpoint will be expressed as the mean staining percentage in tumor tissue.</description>
  </other_outcome>
  <other_outcome>
    <measure>Quantify Antigen-spread</measure>
    <time_frame>up to 3 years post-prostatectomy</time_frame>
    <description>Number of participants with antigen-spread to on-target and off-target antigens.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Enoblituzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Men with localized intermediate and high-risk prostate cancer will be given neoadjuvant Enoblituzumab 15mg/kg IV weekly for 6 weeks followed by radical prostatectomy on day 50, with follow-up visits 30 days and 90 days post-prostatectomy. PSA values will be tracked for 3 years post-prostatectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoblituzumab</intervention_name>
    <description>Enoblituzumab 15mg/kg IV (in the vein) weekly for 6 doses beginning 50 days prior to radical prostatectomy.</description>
    <arm_group_label>Enoblituzumab</arm_group_label>
    <other_name>MGA271</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the prostate (clinical stage T1c-T3b, N0,&#xD;
             M0) without involvement of lymph nodes, bone, or visceral organs&#xD;
&#xD;
          -  Initial prostate biopsy is available for central pathologic review, and is confirmed&#xD;
             to show at least 2 positive cores and a Gleason sum of ≥7&#xD;
&#xD;
          -  Radical prostatectomy has been scheduled at Johns Hopkins Hospital&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  ECOG performance status 0-1, or Karnofsky score ≥ 70% (see Appendix A)&#xD;
&#xD;
          -  Adequate bone marrow, hepatic, and renal function:&#xD;
&#xD;
               -  WBC &gt;3,000 cells/mm3&#xD;
&#xD;
               -  ANC &gt;1,500 cells/mm3&#xD;
&#xD;
               -  Hemoglobin &gt;9.0 g/dL&#xD;
&#xD;
               -  Platelet count &gt;100,000 cells/mm3&#xD;
&#xD;
               -  Serum creatinine &lt;1.5 × upper limit of normal (ULN)&#xD;
&#xD;
               -  Serum bilirubin &lt;1.5 × ULN&#xD;
&#xD;
               -  ALT &lt;3 × ULN&#xD;
&#xD;
               -  AST &lt;3 × ULN&#xD;
&#xD;
               -  Alkaline phosphatase &lt;3 × ULN&#xD;
&#xD;
          -  The etiology of abnormal bilirubin and transaminase levels should be evaluated prior&#xD;
             to study entry.&#xD;
&#xD;
          -  Willingness to provide written informed consent and HIPAA authorization for the&#xD;
             release of personal health information, and the ability to comply with the study&#xD;
             requirements (note: HIPAA authorization will be included in the informed consent)&#xD;
&#xD;
          -  Willingness to use barrier contraception from the time of first dose of MGA271 until&#xD;
             the time of prostatectomy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of known lymph node involvement or distant metastases&#xD;
&#xD;
          -  Other histologic types of prostate cancers such as ductal, sarcomatous, lymphoma,&#xD;
             small cell, and neuroendocrine tumors&#xD;
&#xD;
          -  Prior radiation therapy, hormonal therapy, biologic therapy, or chemotherapy for&#xD;
             prostate cancer&#xD;
&#xD;
          -  Prior immunotherapy/vaccine therapy for prostate cancer&#xD;
&#xD;
          -  Prior use of experimental agents for prostate cancer&#xD;
&#xD;
          -  Concomitant treatment with other hormonal therapy or 5α-reductase inhibitors&#xD;
&#xD;
          -  Current use of systemic corticosteroids or use of systemic corticosteroids within 4&#xD;
             weeks of enrollment (inhaled corticosteroids for asthma or COPD are permitted as are&#xD;
             other non-systemic steroids such as topical corticosteroids)&#xD;
&#xD;
          -  History or presence of autoimmune disease requiring systemic immunosuppression&#xD;
             (including but not limited to: inflammatory bowel disease, systemic lupus&#xD;
             erythematosus, vasculitis, rheumatoid arthritis, scleroderma, multiple sclerosis,&#xD;
             hemolytic anemia, Sjögren syndrome, and sarcoidosis)&#xD;
&#xD;
          -  History of malignancy within the last 3 years, with the exception of non-melanoma skin&#xD;
             cancers and superficial bladder cancer&#xD;
&#xD;
          -  Uncontrolled major active infectious, cardiovascular, pulmonary, hematologic, or&#xD;
             psychiatric illnesses that would make the patient a poor study candidate&#xD;
&#xD;
          -  Known prior or current history of HIV and/or hepatitis B/C&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emmanuel Antonarakis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Sidney Kimmel Comprehensive Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 9, 2016</study_first_submitted>
  <study_first_submitted_qc>September 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2016</study_first_posted>
  <results_first_submitted>July 20, 2021</results_first_submitted>
  <results_first_submitted_qc>August 16, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 24, 2021</results_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>enobilituzumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 8, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/80/NCT02923180/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>33 subjects signed consent to be screened for eligibility.&#xD;
1 subject signed consent, but did not meet the eligibility criteria to start the study (screen failure)&#xD;
32 subjects received study treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Enoblituzumab</title>
          <description>Men with localized intermediate and high-risk prostate cancer will be given neoadjuvant Enoblituzumab 15mg/kg IV weekly for 6 weeks followed by radical prostatectomy on day 50, with follow-up visits 30 days and 90 days post-prostatectomy. PSA values will be tracked for 3 years post-prostatectomy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Off Study Due to Detectable PSA</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Remaining in Long Term Follow Up for PSA</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Enoblituzumab</title>
          <description>Men with localized intermediate and high-risk prostate cancer will be given neoadjuvant Enoblituzumab 15mg/kg IV weekly for 6 weeks followed by radical prostatectomy on day 50, with follow-up visits 30 days and 90 days post-prostatectomy. PSA values will be tracked for 3 years post-prostatectomy.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" spread="5.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking History</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Family History of Prostate Cancer</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ECOG performance status</title>
          <description>The Eastern Cooperative Oncology Group (ECOG) scale measures performance status, with scores ranging from 0-5; 0= fully active, performs without restriction, 1= can ambulate, but restricted in physically strenuous activity, 2= ambulatory and capable of self-care, but unable to work, active for &gt;50% of waking hours, 3= limited self-care, confined to bed or chair for &gt;50% of waking hours, 4= completely disabled, totally confined to bed/chair, 5= deceased</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body-mass index (kg/m2)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Normal (BMI 18.5 - 24.9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overweight (BMI 25.0 - 29.9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Obese (BMI ≥ 30.0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gleason Group / Gleason sum at biopsy</title>
          <description>Gleason grade groups are defined as grade group 1 (Gleason score ≤ 6), grade group 2 (Gleason score 3+4=7), grade group 3 (Gleason score 4+3=7), grade group 4 (Gleason score 8), and grade group 5 (Gleason scores 9-10). A higher grade group reflects a worse outcome.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Grade Group 3: 4+3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade Group 4: 4+4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade Group 5: 4+5, 5+4, or 5+5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous Therapy</title>
          <description>Number of subjects who received therapy for prostate cancer prior to enrollment.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stage T3 at initial diagnosis</title>
          <description>Stage T3 is defined as cancer growth outside of the prostate and possibly spread to the seminal vesicles.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment-related Adverse Events</title>
        <description>Number of participants with treatment-related adverse events as assessed by the Common Terminology Criteria for Adverse Events (CTCAE)v4.0</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Enoblituzumab</title>
            <description>Men with localized intermediate and high-risk prostate cancer will be given neoadjuvant Enoblituzumab 15mg/kg IV weekly for 6 weeks followed by radical prostatectomy on day 50, with follow-up visits 30 days and 90 days post-prostatectomy. PSA values will be tracked for 3 years post-prostatectomy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-related Adverse Events</title>
          <description>Number of participants with treatment-related adverse events as assessed by the Common Terminology Criteria for Adverse Events (CTCAE)v4.0</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Efficacy of Neoadjuvant Enoblituzumab as Assessed by PSA0 Response Rate</title>
        <description>Number of participants with undetectable Prostate Specific Antigen (PSA &lt;0.1 ng/mL) at 12 months following radical prostatectomy</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Enoblituzumab</title>
            <description>Men with localized intermediate and high-risk prostate cancer will be given neoadjuvant Enoblituzumab 15mg/kg IV weekly for 6 weeks followed by radical prostatectomy on day 50, with follow-up visits 30 days and 90 days post-prostatectomy. PSA values will be tracked for 3 years post-prostatectomy.</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy of Neoadjuvant Enoblituzumab as Assessed by PSA0 Response Rate</title>
          <description>Number of participants with undetectable Prostate Specific Antigen (PSA &lt;0.1 ng/mL) at 12 months following radical prostatectomy</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PSA &lt; 0.1 ng/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PSA ≥ 0.1 ng/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quantify Markers of Apoptosis in Prostate Tumor Specimens of Treated Patients</title>
        <description>Quantify markers of apoptosis in prostate tumor specimens of treated patients using TUNEL staining and expressed as the mean staining percentage in tumor tissue</description>
        <time_frame>up to 3 years post-prostatectomy</time_frame>
        <posting_date>07/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Markers of Cell Proliferation</title>
        <description>Quantify markers of cell proliferation in prostate tumor specimens of treated patients using Ki-67 staining and expressed by the mean staining percentage in tumor tissue</description>
        <time_frame>up to 3 years post-prostatectomy</time_frame>
        <posting_date>07/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CD8+ T Cell Infiltration</title>
        <description>Number of CD8+ T-cells in harvested prostate glands from treated patients</description>
        <time_frame>up to 3 years post-prostatectomy</time_frame>
        <posting_date>07/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PD-L1 Expression</title>
        <description>Mean staining percentage of PD-L1 in tumor tissue, assessed by immunohistochemistry (IHC) in the primary core specimens (pre-treatment) and the prostatectomy surgical specimens (post-treatment).</description>
        <time_frame>up to 3 years post-prostatectomy</time_frame>
        <posting_date>07/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Regulatory T Cell (Treg) Infiltration</title>
        <description>Mean staining percentage of Treg cells in tumor tissue of treated patients, assessed through immunohistochemistry.</description>
        <time_frame>up to 3 years post-prostatectomy</time_frame>
        <posting_date>07/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CD4+ T Cell Infiltration</title>
        <description>Mean staining percentage of CD4+ T-cells in tumor tissue of treated patients, assessed through immunohistochemistry.</description>
        <time_frame>up to 3 years post-prostatectomy</time_frame>
        <posting_date>07/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Natural Killer (NK) Cell Density</title>
        <description>Mean staining percentage of NK cells in harvested prostate glands.</description>
        <time_frame>up to 3 years post-prostatectomy</time_frame>
        <posting_date>07/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Enoblituzumab (MGA271) Drug Distribution Evaluated by Detection of MGA271 in Tumor Tissue</title>
        <description>Number of participants with positive or negative MGA271 detection in post-treatment prostate tumor specimens, as evaluated by IHC of fresh frozen sections.</description>
        <time_frame>3 years</time_frame>
        <population>The Overall Number of Participants Analyzed represents those evaluable for this outcome. Of the 32 participants who received study treatment, data from 2 subjects was not evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>Enoblituzumab</title>
            <description>Men with localized intermediate and high-risk prostate cancer will be given neoadjuvant Enoblituzumab 15mg/kg IV weekly for 6 weeks followed by radical prostatectomy on day 50, with follow-up visits 30 days and 90 days post-prostatectomy. PSA values will be tracked for 3 years post-prostatectomy.</description>
          </group>
        </group_list>
        <measure>
          <title>Enoblituzumab (MGA271) Drug Distribution Evaluated by Detection of MGA271 in Tumor Tissue</title>
          <description>Number of participants with positive or negative MGA271 detection in post-treatment prostate tumor specimens, as evaluated by IHC of fresh frozen sections.</description>
          <population>The Overall Number of Participants Analyzed represents those evaluable for this outcome. Of the 32 participants who received study treatment, data from 2 subjects was not evaluable.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pathological Complete Responses (pCR)</title>
        <description>Number of participants who achieve pCR, defined as absence of tumor identification on standard histological analysis of resected prostate specimens.</description>
        <time_frame>3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Enoblituzumab</title>
            <description>Men with localized intermediate and high-risk prostate cancer will be given neoadjuvant Enoblituzumab 15mg/kg IV weekly for 6 weeks followed by radical prostatectomy on day 50, with follow-up visits 30 days and 90 days post-prostatectomy. PSA values will be tracked for 3 years post-prostatectomy.</description>
          </group>
        </group_list>
        <measure>
          <title>Pathological Complete Responses (pCR)</title>
          <description>Number of participants who achieve pCR, defined as absence of tumor identification on standard histological analysis of resected prostate specimens.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PSA Response Rates</title>
        <description>Number of participants with undetectable PSA (&lt;0.1 ng/mL) at 3 months after prostatectomy.</description>
        <time_frame>3 months post-prostatectomy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Enoblituzumab</title>
            <description>Men with localized intermediate and high-risk prostate cancer will be given neoadjuvant Enoblituzumab 15mg/kg IV weekly for 6 weeks followed by radical prostatectomy on day 50, with follow-up visits 30 days and 90 days post-prostatectomy. PSA values will be tracked for 3 years post-prostatectomy.</description>
          </group>
        </group_list>
        <measure>
          <title>PSA Response Rates</title>
          <description>Number of participants with undetectable PSA (&lt;0.1 ng/mL) at 3 months after prostatectomy.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PSA &lt;0.1 ng/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PSA ≥0.1 ng/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to PSA Recurrence</title>
        <description>Median time from prostatectomy to time when PSA is ≥ 0.2 ng/mL. Estimated using Kaplan-Meier method.</description>
        <time_frame>up to 3 years post-prostatectomy</time_frame>
        <posting_date>07/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gleason Grade Group Change</title>
        <description>Number of participants with change in Gleason grade group from pre-treatment biopsy vs. post-treatment biopsy. &quot;Downgrade&quot; refers to a net grade group change less than zero, &quot;upgrade&quot; refers to net grade group change more than zero, and &quot;no change&quot; refers to stable Gleason grade group. Gleason grade groups are defined as grade group 1 (Gleason score ≤ 6), grade group 2 (Gleason score 3+4=7), grade group 3 (Gleason score 4+3=7), grade group 4 (Gleason score 8), and grade group 5 (Gleason scores 9-10).The lower the grade group, the better the outcome.</description>
        <time_frame>Day 50</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Enoblituzumab</title>
            <description>Men with localized intermediate and high-risk prostate cancer will be given neoadjuvant Enoblituzumab 15mg/kg IV weekly for 6 weeks followed by radical prostatectomy on day 50, with follow-up visits 30 days and 90 days post-prostatectomy. PSA values will be tracked for 3 years post-prostatectomy.</description>
          </group>
        </group_list>
        <measure>
          <title>Gleason Grade Group Change</title>
          <description>Number of participants with change in Gleason grade group from pre-treatment biopsy vs. post-treatment biopsy. &quot;Downgrade&quot; refers to a net grade group change less than zero, &quot;upgrade&quot; refers to net grade group change more than zero, and &quot;no change&quot; refers to stable Gleason grade group. Gleason grade groups are defined as grade group 1 (Gleason score ≤ 6), grade group 2 (Gleason score 3+4=7), grade group 3 (Gleason score 4+3=7), grade group 4 (Gleason score 8), and grade group 5 (Gleason scores 9-10).The lower the grade group, the better the outcome.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Downgrade (&lt; 0 net grade group change)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Change (= 0 net grade group change)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upgrade (&gt; 0 net grade group change)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With PSA Percentage Decrease Prior to Radical Prostatectomy.</title>
        <description>The PSA percentage change is calculated as the difference from the PSA at day 50 prior to prostatectomy and PSA at screening. A negative value of PSA percentage change (&quot;PSA percentage &lt; 0&quot;) indicates a decrease in PSA from screening, and a positive value (PSA percentage change &gt;= 0) indicates an increase in PSA from screening.</description>
        <time_frame>50 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Enoblituzumab</title>
            <description>Men with localized intermediate and high-risk prostate cancer will be given neoadjuvant Enoblituzumab 15mg/kg IV weekly for 6 weeks followed by radical prostatectomy on day 50, with follow-up visits 30 days and 90 days post-prostatectomy. PSA values will be tracked for 3 years post-prostatectomy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With PSA Percentage Decrease Prior to Radical Prostatectomy.</title>
          <description>The PSA percentage change is calculated as the difference from the PSA at day 50 prior to prostatectomy and PSA at screening. A negative value of PSA percentage change (&quot;PSA percentage &lt; 0&quot;) indicates a decrease in PSA from screening, and a positive value (PSA percentage change &gt;= 0) indicates an increase in PSA from screening.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PSA percentage change &lt; 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PSA percentage change &gt;= 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Androgen Receptor (AR) Quantification</title>
        <description>Mean staining percentage of AR in harvested prostate tissue, assessed by immunohistochemistry (IHC) staining for AR protein.</description>
        <time_frame>up to 3 years post-prostatectomy</time_frame>
        <posting_date>07/2023</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Tissue Androgen Concentrations</title>
        <description>Concentration (picogram/3 mg) of testosterone and 5α-dihydrotestosterone (DHT) in prostate tissue.</description>
        <time_frame>up to 3 years post prostatectomy</time_frame>
        <posting_date>07/2023</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Global Expression Profiling of Tumor Tissues</title>
        <description>Number of participants with changes in cellular composition, upregulation and downregulation of immune checkpoints, and other markers of activity versus exhaustion.</description>
        <time_frame>up to 3 years post-prostatectomy</time_frame>
        <posting_date>07/2023</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>IHC Analyses of CD137, CD16 and/or CD107A</title>
        <description>CD137, CD107A, and CD16 expression in prostate tumor specimens will be assessed by immunohistochemistry (IHC) in the prostatectomy surgical specimens (post-treatment). This endpoint will be expressed as the mean staining percentage of each of these in tumor tissue</description>
        <time_frame>up to 3 years post-prostatectomy</time_frame>
        <posting_date>07/2023</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>TCR Repertoire</title>
        <description>Number of participants with changes in T-cell receptor (TCR) repertoire, assessed by TCR sequencing.</description>
        <time_frame>up to 3 years post-prostatectomy</time_frame>
        <posting_date>07/2023</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>FC Receptor Genotyping</title>
        <description>Number of participants with CD16A, CD32A, and CD32B on Fc receptor.</description>
        <time_frame>up to 3 years post-prostatectomy</time_frame>
        <posting_date>07/2023</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>PBLs</title>
        <description>Number of participants with upregulation and downregulation of immune checkpoints and other markers of activity versus exhaustion, as assessed by flow cytometry at treatment day 1 (pre-treatment), treatment day 36 (post-treatment), and 30 days post-prostatectomy.</description>
        <time_frame>up to 3 years post-prostatectomy</time_frame>
        <posting_date>07/2023</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>B7-H3 Expression</title>
        <description>B7-H3 expression in prostate tumor specimens will be assessed by IHC (immunohistochemistry) in the primary core specimens (pre-treatment) and in the prostatectomy surgical specimens (post-treatment). This endpoint will be expressed as the mean staining percentage of B7-H3 in tumor tissue.</description>
        <time_frame>up to 3 years post-prostatectomy</time_frame>
        <posting_date>07/2023</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>PD-1, LAG3, and TIM3 Expression</title>
        <description>PD-1, LAG3, and TIM3 expression in prostate tumor specimens will be assessed by IHC (immunohistochemistry) in the primary core specimens (pre-treatment) and in the prostatectomy surgical specimens (post-treatment). This endpoint will be expressed as the mean staining percentage in tumor tissue.</description>
        <time_frame>up to 3 Years post-prostatectomy</time_frame>
        <posting_date>07/2023</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Quantify Antigen-spread</title>
        <description>Number of participants with antigen-spread to on-target and off-target antigens.</description>
        <time_frame>up to 3 years post-prostatectomy</time_frame>
        <posting_date>07/2023</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Enoblituzumab</title>
          <description>Men with localized intermediate and high-risk prostate cancer will be given neoadjuvant Enoblituzumab 15mg/kg IV weekly for 6 weeks followed by radical prostatectomy on day 50, with follow-up visits 30 days and 90 days post-prostatectomy. PSA values will be tracked for 3 years post-prostatectomy.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pericardial Effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Cardiac Disorders - Other, Non-ST-Elevation, Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Right eye stye</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Bloating</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="34" subjects_affected="23" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Flu like symptoms</sub_title>
                <counts group_id="E1" events="17" subjects_affected="13" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Bladder anastomotic leak</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>CD4 lymphocytes decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Serum amylase increased</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Left knee weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Left meniscus tear/injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="31" subjects_affected="31" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Leukocyturia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hemoglobinuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Discolored urine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Urinary frequency</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Cold symptoms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Postnasal drip</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>IV infiltration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Incision site tenderness and erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Loss of dental filling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphocele</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Emmanuel Antonarakis</name_or_title>
      <organization>Johns Hopkins Sidney Kimmel Comprehensive Cancer Center</organization>
      <phone>410-502-8341</phone>
      <email>eantona1@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

